Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Neurology|March 13, 2023
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experimentAlbert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.Clinical Immunology (Orlando, Fla.)|August 7, 2016
Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple SclerosisÁlvaro Cobo-Calvo, Agnes Figueras, Laura Bau, et al.Multiple Sclerosis and Related Disorders|August 27, 2022
The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decadesLucía Romero-Pinel, Laura Bau, Elisabet Matas, et al.Journal of Neurology|June 22, 2026
Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosisAlbert Muñoz-Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.Journal of Neuroimmunology|October 12, 2016
Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosisM Alba Mañé-Martínez, Bob Olsson, Laura Bau, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2015
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosisM Alba Mañé Martínez, Bob Olsson, Laura Bau, et al.Journal of Neurology|December 12, 2023
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohortPablo Arroyo Pereiro, Albert Muñoz-Vendrell, Isabel León Moreno, et al.Frontiers in Immunology|October 27, 2023
Kappa free light chains index in multiple sclerosis very long-term prognosisPablo Arroyo-Pereiro, Lydia García-Serrano, Francisco Morandeira, et al.Multiple Sclerosis and Related Disorders|August 2, 2025
The 2024 McDonald criteria show comparable sensitivity to previous criteria for late-onset multiple sclerosisRaquel Tena-Cucala, Pablo Naval-Baudin, Antonio Martínez-Yélamos, et al.Frontiers in Immunology|November 28, 2024
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosisFernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, et al.Pageof 3